# Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

> **NCT01009801** · PHASE1,PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 27 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** doxorubicin-eluting beads
- **DRUG:** everolimus
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01009801
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-11
- **Final completion:** 2015-06
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** due to slow patient recruitement.
- **Last updated:** 2015-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009801, "Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01009801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*